Novacyt SA (LSE:NCYT) - Share price


Stock Report

Novacyt SA NCYT

Last Price
GBX114.00

Day Change
-5.00|-4.20%

As of 16/08/2022
18:14:22 BST | GBX
Minimum 15 Minutes Delay.

Last Close119.00p
Day Range112.20 - 116.70
Mkt Cap80.14Mil
52-Wk Range104.73 - 497.30
Yield %-
ISINFR0010397232
Volume53,548
P/E1.19
P/S0.01
P/CF0.05

Share Price

Total Returns 16/08/2022

 Chg (%)  
More ...
Novacyt SA-3.39 
FTSE 100 TR GBP5.82
 
Financials
201920202021
More ...
Income Statement
Turnover11.47277.2095.78
Operating Profit-1.06174.92-0.63
Net Profit-3.42132.42-9.73
Reported EPS-8.00194.00-14.00
Balance Sheet
Current Assets5.84204.99158.78
Non Current Assets20.6229.2924.91
Total Assets26.53234.28183.70
Current Liabilities5.8574.1438.90
Total Liabilities14.0783.5741.88
Total Equity12.46150.71141.82
Cash Flow
Operating Cash Flow-1.01123.5535.43
Net Change in Cash0.5189.9710.06

Company Profile

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. Its diagnostic products are used in LBC, oncology, microbiology, hematology, and serology testing. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: Lab21 Product segment is a developer, manufacturer, and distributor of a large range of protein-based infectious disease IVD products; IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Sector

Medical Devices

Index

FTSE AIM All-Share

Next Event 27/09/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-6.62
Op Mrgn-0.01
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorDr. Andrew John William Heath
Non-Executive DirectorDr. Edwin Snape
Executive Director, Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.Mr. Anthony Stephen Dyer
Non-Executive Director, ChairmanMr. James Christopher Wakefield
Non-Executive DirectorMr. Jean-Pierre Jacques Crinelli
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.